Phase I/II clinical trials using hepatitis C virus peptide with the combination therapy of interferon and ribavirin for the patient with chronic hepatitis C

Phase I/II clinical trials using hepatitis C virus peptide with the combination therapy of interferon and ribavirin for the patient with chronic hepatitis C - Hepatitis C virus (HCV) peptide immune therapy for the patient with chronic hepatitis C

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002601

Enrollment

Registered

2009-11-01

Start date

2009-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic hepatitis C

Interventions

HCV peptide and its adjuvant are injected in subcutaneous, once per week, for 48 weeks. At the same time, the combination therapy of peg-interferon and ribavirin are treated.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: HLA typing is HLA-A*2402, 0201, 0206. 20-70 years old. Hepatitis C virus carrier and suffered with chronic hepatitis C. The patient who agreed to enter the trial with the written document. The patients who are considered suitable to enter the trial by the responsible medical doctor.

Exclusion criteria

Exclusion criteria: The patient who has allergy for interferon or ribavirin or other vaccines. Pregnant patients. The patients with autoimmune diseases. The patients with depression. The patients with diabetes mellitus and hypertension.

Design outcomes

Primary

Measure	Time frame
The ratio of sustained viral response for hepatitis C virus, the ratio of rapid viral response for hepatitis C virus, the ratio of early viral response for hepatitis C virus.	—

Secondary

Measure	Time frame
The frequency of adverse events.	—

Countries

Japan

Contacts

Public ContactYoichi Hiasa

Ehime University Graduate School of Medicine Department of Gastroenterology and Metabology

hiasa@m.ehime-u.ac.jp+81-89-960-5308

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026